These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7589502)

  • 21. Molecular modelling of human complement component C3 and its fragments by solution scattering.
    Perkins SJ; Sim RB
    Eur J Biochem; 1986 May; 157(1):155-68. PubMed ID: 3486762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tissue factor residues Lys165 and Lys166 are essential for rapid formation of the quaternary complex of tissue factor.VIIa with Xa.tissue factor pathway inhibitor.
    Rao LV; Ruf W
    Biochemistry; 1995 Aug; 34(34):10867-71. PubMed ID: 7662667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure of the extracellular domain of human tissue factor: location of the factor VIIa binding site.
    Muller YA; Ultsch MH; Kelley RF; de Vos AM
    Biochemistry; 1994 Sep; 33(36):10864-70. PubMed ID: 8086403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dimerization of tissue factor supports solution-phase autoactivation of factor VII without influencing proteolytic activation of factor X.
    Doñate F; Kelly CR; Ruf W; Edgington TS
    Biochemistry; 2000 Sep; 39(37):11467-76. PubMed ID: 10985793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended and flexible domain solution structure of the extracellular matrix protein anosmin-1 by X-ray scattering, analytical ultracentrifugation and constrained modelling.
    Hu Y; Sun Z; Eaton JT; Bouloux PM; Perkins SJ
    J Mol Biol; 2005 Jul; 350(3):553-70. PubMed ID: 15949815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural modulation of factor VIIa by full-length tissue factor (TF
    Prasad R; Sen P
    J Biomol Struct Dyn; 2018 Feb; 36(3):621-633. PubMed ID: 28150568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG: a study by X-ray and neutron solution scattering and homology modelling.
    Boehm MK; Woof JM; Kerr MA; Perkins SJ
    J Mol Biol; 1999 Mar; 286(5):1421-47. PubMed ID: 10064707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tissue factor and its extracellular soluble domain: the relationship between intermolecular association with factor VIIa and enzymatic activity of the complex.
    Waxman E; Ross JB; Laue TM; Guha A; Thiruvikraman SV; Lin TC; Konigsberg WH; Nemerson Y
    Biochemistry; 1992 Apr; 31(16):3998-4003. PubMed ID: 1567850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loop dynamics of the extracellular domain of human tissue factor and activation of factor VIIa.
    Minazzo AS; Darlington RC; Ross JB
    Biophys J; 2009 Jan; 96(2):681-92. PubMed ID: 19167313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factor VIIa's first epidermal growth factor-like domain's role in catalytic activity.
    Jin J; Chang J; Chang JY; Kelley RF; Stafford DW; Straight DL
    Biochemistry; 1999 Jan; 38(4):1185-92. PubMed ID: 9930978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of residue Phe225 in the cofactor-mediated, allosteric regulation of the serine protease coagulation factor VIIa.
    Petrovan RJ; Ruf W
    Biochemistry; 2000 Nov; 39(47):14457-63. PubMed ID: 11087398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitors of factor VIIa affect the interface between the protease domain and tissue factor.
    Carlsson K; Persson E; Carlsson U; Svensson M
    Biochem Biophys Res Commun; 2006 Oct; 349(3):1111-6. PubMed ID: 16970919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of blood coagulation factor VIIa with cleaved tissue factor extracellular domain and crystallization of the active complex.
    Kirchhofer D; Guha A; Nemerson Y; Konigsberg WH; Vilbois F; Chène C; Banner DW; D'Arcy A
    Proteins; 1995 Aug; 22(4):419-25. PubMed ID: 7479715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa.
    Dickinson CD; Kelly CR; Ruf W
    Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14379-84. PubMed ID: 8962059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses.
    Ashton AW; Boehm MK; Gallimore JR; Pepys MB; Perkins SJ
    J Mol Biol; 1997 Sep; 272(3):408-22. PubMed ID: 9325100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue factor and factor VIIa: understanding the molecular mechanism.
    Morrissey J; Mackman N
    Thromb Res; 2008; 122 Suppl 1(Suppl 1):S1-2. PubMed ID: 18691490
    [No Abstract]   [Full Text] [Related]  

  • 37. Two sites in the tissue factor extracellular domain mediate the recognition of the ligand factor VIIa.
    Ruf W; Edgington TS
    Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8430-4. PubMed ID: 1924302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Importance of factor VIIa Gla-domain residue Arg-36 for recognition of the macromolecular substrate factor X Gla-domain.
    Ruf W; Shobe J; Rao SM; Dickinson CD; Olson A; Edgington TS
    Biochemistry; 1999 Feb; 38(7):1957-66. PubMed ID: 10026279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What causes the enhancement of activity of factor VIIa by tissue factor?
    Colina CM; Venkateswarlu D; Duke R; Perera L; Pedersen LG
    J Thromb Haemost; 2006 Dec; 4(12):2726-9. PubMed ID: 17002651
    [No Abstract]   [Full Text] [Related]  

  • 40. Four loops of the catalytic domain of factor viia mediate the effect of the first EGF-like domain substitution on factor viia catalytic activity.
    Jin J; Perera L; Stafford D; Pedersen L
    J Mol Biol; 2001 Apr; 307(5):1503-17. PubMed ID: 11292356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.